AstraZeneca blames customer cut backs for disappointing results
Friday 25 April 2008
The Anglo-Swedish pharmaceutical group AstraZeneca posted what analysts considered to be disappointing first-quarter sales figures yesterday, but said that its full-year earnings growth was on track to meet expectations.
The company blamed customers cutting back on stocks of drugs in the first quarter as the main reason for the numbers, which showed 10 per cent sales growth, below forecasts. The group manufacturers Nexium, the blockbuster ulcer treatment, which had faced a patent challenge from the Indian generics company Ranbaxy that was resolved in AstraZeneca's favour last week.
Analysts expected that Nexium sales growth would be slower, but were mystified why other drugs had also been de-stocked. Simon Louth, AstraZeneca's chief financial officer, said there was "no particular reason".
First-quarter, pre-tax profits were up 12 per cent to $2.65bn (£1.34bn), although this figure did not include restructuring costs associated with the buyout of the biotechnology group MedImmune. Shares in the company fell by 5 per cent on the announcement, with analysts blaming a misunderstanding of the figures. The group has said that due to beneficial movements in the dollar, earnings per share growth had increased by 5 cents.
Peter Cartwright, an analyst at Evolution, said that most investors had assumed that the growth increase had been worked out by taking a set dollar price for the whole year, when in fact it is worked out by the company on a quarterly basis. Shares had recovered to 2,120p by the close of trading, down 0.6 per cent, with investors assuming that the 5 cent figure will improve during the year.
Despite the group maintaining that it will hit annual sales targets, Simon Mather, a pharmaceutical industry watcher at WestLB, said the company would come under pressure in the next year, particularly from generics groups.
The patents of Seroquel, the company's psychiatric treatment, and Crestor, an anti-cholesterol drug, face challenges in the next 18 months. Mr Louth said he would vigorously defend its intellectual property rights.
Seroquel recorded sales of $1.05bn in the first quarter, up from $923m last year, while Crestor made $772m against $628m in 2006.
Mr Louth also refused to rule out a move away from the UK. Last week, one of AstraZeneca's rivals, Shire, said it was to re-domicile in the Republic of Ireland to take advantage of the country's 12.5 per cent corporate tax rate. UK corporate tax is charged at 28 per cent.
filmFilm producers sue Warner Bros for $75m over Hobbit films
sportNapoli 2 Arsenal 0: Gunners must now face either Real Madrid, PSG, Bayern Munich, Atletico Madrid or Barcelona in knock-out stages
Swedish stars ask fans for £195 pledges on crowd-funding website
voicesJust when you thought you could find a man, get married, and have a baby by the age of 35... it turns out you’re too late, says Grace Dent
musicAs Mariah Carey and Noddy Holder rake in the royalties from their classics, why there hasn't been a decent festive hit for 20 years?
theatreAuthor Daniel Rosenthal recalls the mishaps that almost brought the curtain down on the likes of John Gielgud and Diana Rigg
lifeAs the Royal Mail plans to phase out deliveries on two wheels, it's no wonder posties are in a spin
musicThe 21-year-old beat Ella Eyre and Chlöe Howl to win the honour
lifeFull of the joys and want to help your fellow man? December isn't the time to do it
techLuke Blackall reports on precision engineered prams and babygros that monitor your child 24-7
Nelson Mandela memorial: ‘Bogus’ interpreter made mockery of Barack Obama’s tribute in Soweto
David Cameron explains selfie with Obama and Helle Thorning-Schmidt at Mandela Memorial
French café starts charging extra to rude customers
Krokodil in Mexico? Teenager hospitalised after 'injecting drug into her genitals'
Australia incest case: Severely deformed children found in remote farming community after generations of inbreeding
- 1 Nelson Mandela memorial: ‘Bogus’ interpreter made mockery of Barack Obama’s tribute in Soweto
- 2 French café starts charging extra to rude customers
- 3 Sun will 'flip upside down' within weeks, says Nasa
- 4 Is Facebook making us forget? Study shows that taking pictures ruin memories
- 5 Australia incest case: Severely deformed children found in remote farming community after generations of inbreeding
iJobs Money & Business
£77099.84 - £96375.26 per annum + Bonus + Benefits : Harrington Starr: My clie...
£45000 - £60000 per annum + Bonus and Package: Harrington Starr: Trading appli...
£50000 - £60000 per annum + BONUS + BENEFITS: Harrington Starr: A leading prov...
£70000 - £90000 per annum + BONUS + BENEFITS: Harrington Starr: A leading mark...